UCB Beats on Revs – Zacks.com

by admin on February 28, 2013

UCB Beats on Revs
Neupro, which is marketed as a treatment for Parkinson's disease (PD) and restless legs syndrome (RLS), recorded sales of €133 million, up 38%. However, sales of Keppra, another epilepsy treatment, declined 16% to €838 million in 2012. Sales were hurt

and more »

View full post on restless leg syndrome – Google News

Leave a Comment

Previous post:

Next post: